Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 5/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.37 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | IDH2 | P48735 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31038939 | 1.00 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRA3ADRB1 | |
| Formamide SCHEMBL6983800 | 0.89 | GABRA1 (0.43) | GABRA1GABRG2GABRB3GABRA3ADRB1 | |
| SCHEMBL31543495 | 0.84 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRA3ADRB1 | |
| SCHEMBL1661164 | 0.84 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRA3ADRB1 | |
| SCHEMBL30632766 | 0.83 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRA3ADRB1 | |
| SCHEMBL26686630 | 0.83 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRA3ADRB1 | |
| SCHEMBL2014949 | 0.83 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRA3ADRB1 | |
| SCHEMBL16115627 | 0.79 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRA3LOXL2 | |
| SCHEMBL7171955 | 0.79 | CYP3A4 (0.46) | GABRA1GABRG2GABRB3GABRA3GAA | |
| SCHEMBL15094782 | 0.78 | IDH1 (0.48) | GABRA1GABRG2GABRB3GABRA3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688155-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | Bial-Portela & CA, S.A. (PT) | 2026-02-11 | — | — | EP | claimed |
| WO-2025023852-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | claimed |
| CN-110821065-B | Exterior wall coating construction method | 深圳陆城装饰设计工程有限公司 | 2022-01-14 | — | — | CN | claimed |
| CN-110821065-A | Exterior wall coating construction method | 深圳陆城装饰设计工程有限公司 | 2020-02-21 | — | — | CN | claimed |
| CN-110003117-A | A kind of ferulic amide derivative and its preparation and use containing trifluoromethyl pyrimidine | 贵阳学院 | 2019-07-12 | — | — | CN | claimed |
| CN-106188013-A | A kind of synthetic method of 6 trifluoromethyl N (2 trifluoro methyl indole 5 base) methyl 4 pyrimidinamine | 中国药科大学 | 2016-12-07 | — | — | CN | claimed |
| CN-102887860-B | Preparation method of 4-chloro-6-trifluoromethylpyrimidine type compound | SHANGHAI TITAN TECHNOLOGY CO LTD | 2015-07-01 | — | — | CN | claimed |
| CN-101792420-B | Preparation of halogenated n-heteroaromatic polyhalogen derivatives | SALTIGO GMBH (DE) | 2014-10-08 | — | — | CN | claimed |
| CN-102887860-A | Preparation method of 4-chloro-6-trifluoromethylpyrimidine type compound | SHANGHAI TITAN TECHNOLOGY CO LTD | 2013-01-23 | — | — | CN | claimed |
| CN-101792420-A | Preparation of halogenated n-heteroaromatic polyhalogen derivatives | SALTIGO GMBH | 2010-08-04 | — | — | CN | claimed |
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-117659017-B | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2026-05-15 | — | — | CN | disclosed |
| EP-4731623-A1 | CARBOLINE COMPOUNDS AND USE THEREOF | PTC Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| EP-0937722-A1 | Benzimidazole derivatives as cyclooxygenase-2 inhibitors | PFIZER INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| CN-1214339-A | Pyrazole derivatives, their preparation and their use in pharmaceuticals | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-04-21 | — | — | CN | disclosed |
| EP-0908456-A1 | Pyrazole derivatives, their preparation and their use in drugs | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-04-14 | — | — | EP | disclosed |
| EP-0806422-A2 | Anti-cataract agent | Senju Pharmaceutical Co., Ltd. (JP) | 1997-11-12 | — | — | EP | disclosed |
| EP-0163280-A1 | Pyrimidylphosphoric acid esters, process for their preparation and their use for pest control | BASF Aktiengesellschaft (DE) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | GABRA1 223/4885GABRG2 190/4885GABRB3 282/4885 |
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | CLIC1, CYP2B6, CYP2D6 | GABRA1 483/4885GABRG2 1823/4885GABRB3 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.